# US 2023/0117592 A1 · Lipoxygenase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0117592 A1
- Document ID: US20230117592A1
- Status: Published application
- Kind: A1
- Application number: 17/788,275
- Filed: 2020-12-18
- Published: 2023-04-20
- Earliest claimed: 2019-12-23
- Assignees: SRI International
- Applicants: SRI International
- Inventors: Ling Jong; Nathan Collins; Raymond Ng
- Web page: https://patentgrep.com/patent/US20230117592A1

## CPC

- C07C 217/86: to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
- C07C 211/49: having at least two amino groups bound to the carbon skeleton
- C07C 211/50: with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C 211/53: having the nitrogen atom of at least one of the amino groups further bound to a hydrocarbon radical substituted by amino groups
- C07C 211/54: having amino groups bound to two or three six-membered aromatic rings
- C07C 211/56: the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
- C07C 215/80: containing at least two amino groups bound to the carbon skeleton
- C07C 215/82: having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of another six-membered aromatic ring
- C07C 217/92: the nitrogen atom of at least one of the amino groups being further bound to a carbon atom of a six-membered aromatic ring
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 215/24: attached in position 8
- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 257/04: Five-membered rings
- C07D 295/125: with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D 295/13: to an acyclic saturated chain
- C07D 305/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- C07D 309/04: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.

## Claims

### Claim 1

A compound having Formula I:
wherein:
n is 0-2, such that when n=0, there is a direct bond between B and the NH group and with no R3, and when n=1 or 2, the carbons in these bonds are optionally substituted with one R3 group;
A is a 6 membered heteroaryl or a 6 membered aryl, wherein the 6 membered heteroaryl or 6 membered aryl is further independently substituted with one to three R1 groups;
B is a 5-6-membered heterocycle, a 5-6 membered aryl, or a 5-6 membered cyclohexyl, wherein the 5-6 membered heterocycle, 5-6 membered aryl, or 5-6 membered cyclohexyl is unsubstituted or independently substituted with up to three R2 groups;
each X1, X2, X3, X4, X5, and X6 independently comprising: C, N, or O;
each R1 independently comprising: halo, C1-4 alkyl, —NRxRy, —O(CH2)2Rx, —O(CH2)2NRxRy, —NHC(O)—C2-4 alkyl, —(CH2)3NRxRy, —NH(CH2)2RxRy, —NHCH2CRxRyRz, a 5-6 membered aryl, a 5-10 membered heterocycle, a 5-10 membered heteroaryl, or a 5-10 membered heterocyclic aryl,
wherein the one to three R1 groups are optionally further substituted with Ra and/or Rb,
wherein two R1 groups optionally come together to form a 5-6 membered heteroaryl, [5-6 membered heterocycle, 5-6 membered cycloalkyl, 5-6 membered aryl], wherein the 5-6 membered heteroaryl, [5-6 membered heterocycle, 5-6 membered cycloalkyl, 5-6 membered aryl] is optionally further substituted with one to three Ra groups;
each R2 independently comprising: halo, C1-2 methoxy, or —C(O)ORx;
wherein two R2 groups on adjacent atoms optionally come together to from a 5-6 membered aryl, wherein the 5-6 membered aryl is optionally further substituted with one to three Ra groups;
R3 comprising: C1-3 haloalkyl, or oxo;
Rx, Ry, and Rz each independently comprising: H, halo, C1-2 alkyl, C1-2 alcohol, C1-2 alkoxy, C1-2 haloalky, or —NRaRb, wherein any two of Rx, Ry, or Rz optionally come together to form a 4-6 membered heterocycle, 5-6 membered aryl, wherein Rx, Ry, and Rz are each optionally further substituted with Ra and Rb;
Ra and Rb each independently comprising: H, halo, cyano, oxo, C1-3 alkyl, —C(O)OR′, C1-3 haloalkyl, 5-6 membered aryl, 5-6 membered heteroaryl, or 4-6 membered heterocycle,
wherein Ra and Rb are each optionally further substituted with R′;
R′ is C1-3 alkyl, C1-3 haloalkyl, or C5-6 membered heteroaryl; and
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein each R1 is independently selected from:

### Claim 3 (depends on 1)

The compound of claim 1, wherein each R2 is independently selected from:

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is selected from:
and pharmaceutically acceptable salts thereof.

### Claim 5

A compound having Formula II,
wherein:
A is a 6 membered heteroaryl or a 6 membered aryl, wherein the 6 membered heteroaryl or 6 membered aryl is independently substituted with one to three R1 groups;
B is a 6 membered heterocycle, a 6 membered aryl, or a 6 membered cyclohexyl, wherein the 6 membered heterocycle, 6 membered aryl, or 6 membered cyclohexyl is either unsubstituted or independently substituted with up to two R2 groups;
each X1, X2, X3, and X4 independently comprising: C, N, or O;
each R1 independently comprising: halo, C1-4 alkyl, —NRxRy, —O(CH2)2RxRy, —O(CH2)2NRxRy, —NHC(O)-alkyl(2-4), —(CH2)3NRxRy, —NH(CH2)2RxRy, —NHCH2CRxRyRz, a 5-6 membered aryl, a 5-10 membered heterocycle, a 5-10 membered heteroaryl, or a 5-10 membered heterocyclic aryl,
wherein two R1 groups optionally come together to form a 5-6 membered heteroaryl, [5-6 membered heterocycle, 5-6 membered cycloalkyl, 5-6 membered aryl], wherein the 5-6 membered heteroaryl, [5-6 membered heterocycle, 5-6 membered cycloalkyl, 5-6 membered aryl] is optionally further substituted with one to three Ra groups,
wherein each of the one to three R1 groups are optionally independently further substituted with Ra or Rb;
each R2 independently comprising halo, C1-2 methoxy, or —C(O)ORx;
each Rx, Ry, and Rz independently comprising: H, halo, C1-2 alkyl, C1-2 alcohol, C1-2 alkoxy, C1-2 haloalkyl, or —NRaRb,
wherein two of Rx, Ry, or Rz optionally come together to form a 4-6 membered heterocycle, 5-6 membered aryl, wherein each of the Rx, Ry, and Rz are optionally further substituted with Ra and Rb;
Ra and Rb each independently comprising: H, halo, cyano, oxo, C1-3 alkyl, —C(O)OR′, C1-3 haloalkyl, a 5-6 membered aryl, a 5-6 membered heteroaryl, or a 4-6 membered heterocycle,
wherein Ra and Rb are optionally and independently further substituted with R′;
R′ is C1-3 alkyl, C1-3 haloalkyl, or a 5-6 membered heteroaryl; and
a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5, wherein each R1 is independently selected from:

### Claim 7 (depends on 5)

The compounds of claim 5, wherein each R2 is independently selected from:

### Claim 8 (depends on 5)

The compounds of claim 5, wherein the compound is selected from:
and pharmaceutically acceptable salts thereof.

### Claim 9

A compound having Formula IIA:
wherein:
B is cyclohexyl, a 6-membered heterocycle, a 6-membered aryl, or a 6-membered heteroaryl;
X1, X3, and X4 are each independently C, N, or O;
R1 is —C1-3 alkyl-Rx, —(CH2)2NRxRy, —CH2C(RxRy)Ra, —CH2C(RxRy)NRaRb, or a 5-6 membered aryl, wherein R1 is optionally further substituted with Ra or Rb;
R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, or C1-3 haloalkoxy,
wherein R1 and R2 optionally come together to form a 5-6 membered heterocycle, wherein the 5-6 membered heterocycle is optionally further substituted with Ra, Rb, or both Ra and Rb;
R3 is H or halo;
R4 is halo, or C1-3 alkyl;
Rx and Ry are each independently a C5-6 membered heterocycle,
Ra and Rb are each independently C1-3 alkyl or C1-3 haloalkyl,
wherein Ra and Rb are optionally further substituted with a R′ group;
R′ group is a 5 membered heteroaryl or a 5-6 membered heterocycle; and
pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is selected from:

### Claim 11 (depends on 9)

The compound of claim 9, wherein each R2 is independently selected from:

### Claim 12 (depends on 9)

The compound of claim 9, wherein the compound is selected from:
and pharmaceutically acceptable salts thereof.

### Claim 13

A compound having Formula IIB:
wherein:
B is cyclohexyl, a 6 membered heterocycle, a 6 membered aryl, or a 6 membered heteroaryl;
each X is independently C, N, or O;
R1 is H, C1-3 alkyl, a 5-6 membered heterocycle, a 5-6 membered aryl, a 5-6 membered heteroaryl, a 5-10 membered cycloheteroaryl, a 5-10 membered heteroaryl, or —C(O)Rx;
R2a and R2b are each independently: H, C1-3 alkyl, a 5-6 membered aryl, —NRx(CH2)2Ry, —NRx(CH2)3Ry, —NRxC(O)(CH2)2Ry, —NH(CH2)2NRxRy, —O(CH2)2Rx, —NH(CH2)CRxRyCH2Ra, —NH(CH2)CRxRyCH2NRaRb, —(CH2)3NRxRy, a 5-10 membered cycloheteroaryl, or —NRxRy;
R′2 is H or a halo;
each R3 is independently H, halo, C1-3 alkyl, —O(CH2)2NRxRy, —NRx(CH2)2Ry, —NRxRy, or —(CH2)3NRxRy;
R4 is halo;
further wherein R1 with either R2a or R2b optionally come together to form a 5-6 membered heterocycle, the 5-6 membered heterocycle is optionally further substituted with one or more of Ra and Rb, and
wherein R1, R2a, R2b, R′2, and R3 are each optionally and independently substituted with one or more Ra;
Rx and Ry are each independently H, C1-4 alkyl, 5-6 membered aryl, 5-6 membered heteroaryl, —NRaRb,
wherein Rx and Ry each optionally come together to form 4-5 membered heterocycle, and
wherein Rx or Ry optionally and independently are further substituted with Ra and/or Rb;
Ra and Rb are each independently H, halo, oxo, cyano, C1-3 alkyl, C1-3 alcohol, C1-3 alkoxy, phenyl, —(CH2)2R′, 5-6 membered heteroaryl, or 5-6 membered heterocycle;
R′ is a 5 membered heteroaryl; and
pharmaceutically acceptable salts thereof.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R1 is selected from:

### Claim 15 (depends on 13)

The compound of claim 13, wherein R2a and R2b are each independently selected from:

### Claim 16 (depends on 13)

The compound of claim 13, wherein each R3 is independently H,

### Claim 17 (depends on 13)

The compound of claim 13, wherein the compound is selected from:
and pharmaceutically acceptable salts thereof.

### Claim 18

A compound having Formula III:
wherein:
n is 1-2;
B is a cyclohexyl, a 6-membered heterocycle, a 6-membered aryl, or a 6-membered heteroaryl;
X1, X2, X3, X4, and X5 are each independently C, N, or O;
R1 is halo, C1-4 alkyl, —NRxRy, —O(CH2)2NRxRy, a 6 membered cyclohexyl, a 6 membered heterocycle, a 6 membered aryl, a 6 membered heteroaryl, or a 5-10 membered cycloalkyl,
wherein when there are two R1 groups, the two R1 groups optionally come together to form a 6 membered heteroaryl;
wherein each R1 is optionally and independently further substituted with one or more Ra;
each R2 is halo or C1-3 alkoxy;
each R3 is independently H, oxo, C1-3 haloalkyl, or a hydroxyalkyl,
wherein when one or more R3 is hydroxyalkyl, the one or more of R3 optionally comes together with a C of Formula III to form a 4 membered heterocycle;
Rx and Ry are each independently H, C1-3 alkyl, a 6 membered aryl, or a 6 membered heteroaryl,
wherein Rx and Ry are each optionally and independently further substituted with one or more Ra;
Ra is halo, oxo, cyano, C1-3 haloalkyl, —NR′R′, a 5-6 membered aryl, a 5-6 membered heteroaryl, or a 5-6 membered heterocycle, and
wherein the one or more Ra optionally come together to form a 4-5 membered heterocycle;
R′ is C1-3 alkyl; and
pharmaceutically acceptable salts thereof.

### Claim 19 (depends on 18)

The compound of claim 18, wherein each R1 is independently selected from:

### Claim 20 (depends on 18)

The compound of claim 18, wherein each R2 is independently: H,

### Claim 21 (depends on 18)

The compound of claim 18, wherein R3 is: H, oxo, or

### Claim 22 (depends on 18)

The compound of claim 18, wherein the compound is selected from:
and pharmaceutically acceptable salts thereof.

### Claim 23

A compound having Formula IIIA:
wherein:
n is 1-2;
B is a cyclohexyl, a 6-membered heterocycle, a 6-membered aryl, or a 6-membered heteroaryl;
X1, X2, and X3 are each independently C, N, or O;
R1 is C1-3 alkyl,
wherein R1 is optionally substituted with one or more Ra or Rb;
R2 is H, halo, C1-3 haloalkyl, C1-4 alkyl, 5-6 membered aryl, 5-6 membered cycloalkyl, 5-6 membered heterocycle, 5-10 membered heteroaryl, 5-10 membered cycloaryl;
R3 is H or halo;
each R4 is independently H, oxo, a C1-3 haloalkyl, or a hydroxyalkyl,
wherein when one or more of R4 is hydroxyalkyl, the one or more R4 optionally comes together with a C of the Formula IIIA to form a 4 membered heterocycle;
R5 is halo, or a 4-5 membered heterocycle;
R1, R2, R4, and R5 are each optionally and independently be substituted with up to two Ra or Rb;
Ra and Rb are each independently C1-3 alkyl, C1-3 haloalkyl, 5-6 membered heterocycle, 5-6 membered heteroaryl, —N/—NR′R′,
wherein an Ra and Rb optionally come together to form a 4-5 membered heterocycle,
wherein Ra and Rb are each optionally and independently further substituted with one or more R′ groups;
R′ is halo or C1-3 alkyl; and
pharmaceutically acceptable salts thereof.

### Claim 24 (depends on 23)

The compound of claim 23, wherein R1 is selected from:

### Claim 25 (depends on 23)

The compound of claim 23, wherein R2 is selected from:

### Claim 26 (depends on 23)

The compound of claim 23, wherein R3 is H or F.

### Claim 27 (depends on 23)

The compound of claim 23, wherein R4 is: H,

### Claim 28 (depends on 23)

The compound of claim 23, wherein R5 is

### Claim 29 (depends on 23)

The compound of claim 23, wherein the compound is selected from:
and pharmaceutically acceptable salts thereof.

### Claim 30

A compound having Formula IIIB:
wherein:
n is 1-2;
B is a cyclohexyl, a 6-membered heterocycle, a 6-membered aryl, or a 6-membered heteroaryl;
X1, X2, X3 and X4 are each independently C or N;
R1 is H, a C1-3 alkyl, or a 5-6 membered aryl;
wherein R1 is optionally substituted with one or more Ra or Rb;
R2a and R2b are each independently C1-4 alkyl, or a 5-6 membered heteroaryl;
R1 and R2a, or R2b optionally come together to form a 5-6 membered aryl or 5-6 membered heteroaryl, the optional 5-6 membered aryl or 5-6 membered heteroaryl being optionally further substituted with Ra and Rb;
R3 is H, halo, or C1-3 alkoxy;
each R4 is independently H or oxo;
R5 is halo or a 4-5 membered heterocycle;
R1, R2a, R2b, R3, and R5 are each independently and optionally further substituted with Ra and Rb;
Ra and Rb are each independently H, halo, oxo, cyano, or a C1-3 alkyl, 5-6 membered heteroaryl; and
pharmaceutically acceptable salts thereof.

### Claim 31 (depends on 30)

The compound of claim 30, wherein R1 is:

### Claim 32 (depends on 20)

The compound of claim 20, wherein R2a and R2b are each independently: H,

### Claim 33 (depends on 30)

The compound of claim 30, wherein R3 is: H or

### Claim 34 (depends on 30)

The compound of claim 30, wherein R4 is: H or oxo.

### Claim 35 (depends on 30)

The compound of claim 30, wherein each R5 is independently:

### Claim 36 (depends on 30)

The compound of claim 30, wherein the compound is selected from:
and pharmaceutically acceptable salts and/or hydrates thereof.
